Bio-Path (NASDAQ:BPTH – Get Free Report) is expected to be announcing its earnings results before the market opens on Thursday, March 6th. Analysts expect the company to announce earnings of ($0.37) per share for the quarter.
Bio-Path Price Performance
BPTH stock opened at $0.18 on Tuesday. The company’s fifty day moving average price is $0.75 and its 200-day moving average price is $0.89. Bio-Path has a one year low of $0.12 and a one year high of $7.67.
Wall Street Analyst Weigh In
Separately, StockNews.com initiated coverage on shares of Bio-Path in a research note on Sunday. They set a “sell” rating on the stock.
About Bio-Path
Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
Further Reading
- Five stocks we like better than Bio-Path
- Learn Technical Analysis Skills to Master the Stock Market
- Bearish Investors Can Seek Refuge in Recession-Resistant ETFs
- How to Profit From Growth Investing
- 3 Oversold Magnificent Seven Stocks at Key Levels: Buy Now?
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- 3M to Hit $175 by Mid-Year, and Higher Highs Are Likely
Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.
